echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Icotinizumab can effectively reduce the number of migraine days per month in patients with chronic migraine

    Neurology: Icotinizumab can effectively reduce the number of migraine days per month in patients with chronic migraine

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Migraine is a common disabling neurological disease, and the most difficult one is chronic migraine (CM).


    prevention

    Adults with CM were included in the study and were randomly assigned to receive IV Ictizumab 100 mg, Ictizumab 300 mg or placebo, administered on day 0 and week 12.


     

    The results showed that among the treated participants (n = 1,072), the average number of MMDs in each group at baseline was ≈16.


    Figure 1.


    To sum up, the results of this study show that in the middle plexus of CM patients, from the 2nd day to the 12th week after intravenous administration, Icotinizumab 100 and 300 mg are related to the significant reduction of MMDs, the tolerance and Security is good.


     

    Original source:

     

    Richard B Lipton, Peter J Goadsby, et al.


    ncbi.
    nlm.
    nih.
    gov/32209650/" target="_blank" rel="noopener">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.